Candel Therapeutics, Inc. (CADL)
6.20
-2.19
(-26.10%)
USD |
NASDAQ |
Nov 13, 16:00
6.05
-0.15
(-2.42%)
After-Hours: 19:59
Candel Therapeutics Enterprise Value : 333.02M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 333.02M |
| November 12, 2026 | 504.82M |
| November 11, 2026 | 569.93M |
| November 10, 2026 | 580.12M |
| November 09, 2026 | 591.11M |
| November 06, 2026 | 533.06M |
| November 05, 2026 | 477.36M |
| November 04, 2026 | 556.59M |
| November 03, 2026 | 538.55M |
| November 02, 2026 | 483.63M |
| October 30, 2026 | 500.11M |
| October 29, 2026 | 525.21M |
| October 28, 2026 | 526.78M |
| October 27, 2026 | 493.83M |
| October 26, 2026 | 457.75M |
| October 23, 2026 | 476.57M |
| October 22, 2026 | 504.03M |
| October 21, 2026 | 503.25M |
| October 20, 2026 | 524.43M |
| October 19, 2026 | 490.69M |
| October 16, 2026 | 489.13M |
| October 15, 2026 | 545.61M |
| October 14, 2026 | 558.16M |
| October 13, 2026 | 573.85M |
| October 12, 2026 | 613.85M |
| Date | Value |
|---|---|
| October 09, 2026 | 626.41M |
| October 08, 2026 | 604.44M |
| October 07, 2026 | 616.99M |
| October 06, 2026 | 620.92M |
| October 05, 2026 | 649.16M |
| October 02, 2026 | 645.23M |
| October 01, 2026 | 643.66M |
| September 30, 2026 | 665.63M |
| September 29, 2026 | 676.12M |
| September 28, 2026 | 699.72M |
| September 25, 2026 | 686.78M |
| September 24, 2026 | 727.12M |
| September 23, 2026 | 707.33M |
| September 22, 2026 | 749.95M |
| September 21, 2026 | 701.24M |
| September 18, 2026 | 673.84M |
| September 17, 2026 | 711.13M |
| September 16, 2026 | 686.78M |
| September 15, 2026 | 694.39M |
| September 14, 2026 | 660.51M |
| September 11, 2026 | 650.62M |
| September 10, 2026 | 710.37M |
| September 09, 2026 | 774.31M |
| September 08, 2026 | 807.04M |
| September 04, 2026 | 820.74M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Oragenics, Inc. | -0.9239M |
| Arcturus Therapeutics Holdings, Inc. | 74.98M |
| ACADIA Pharmaceuticals, Inc. | 2.335B |
| Alnylam Pharmaceuticals, Inc. | 21.50B |
| Anika Therapeutics, Inc. | 160.67M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.87M |
| Total Expenses (Quarterly) | 21.87M |
| EPS Diluted (Quarterly) | -0.2826 |
| Earnings Yield | -23.98% |
| Normalized Earnings Yield | -20.84 |